BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French |
Published |
17.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL eligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin/carboplatin).
L'invention concerne des méthodes de traitement clinique de lymphome diffus à grandes cellules B (DLBCL) (par exemple, d'un DLBCL de rechute et/ou réfractaire éligible à une greffe de cellules souches autologues) chez des sujets humains à l'aide d'un anticorps bispécifique qui se lie à CD3 et à CD20 en combinaison avec un standard de régime de soins de R-DHAX/C (Rituximab, Dexaméthasone, Cytarabine, et Oxaliplatine/Carboplatine). |
---|---|
Bibliography: | Application Number: WO2021EP75021 |